GLP-1 receptor agonists × glycemic control

TrialLancet (London, England)2009

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.

Alan Garber et al.PubMed ↗Publisher ↗

  • Liraglutide 1.2 mglooks good hereLower long-term blood sugar.Randomised, small.
  • Liraglutide 1.8 mglooks good hereLower long-term blood sugar.Randomised, small.

What the trial testedrandomised · 746 people · 2009

Randomised vs glimepiride 8 mg

Probably lowered long-term blood sugar

−0.33percentage points−0.53 to −0.13

liraglutide 1.2 mg vs glimepiride 8 mg

As reported

difference −0.33 %, 95% CI −0.53 to −0.13 · the paper's word: change in proportion of glycosylated haemoglobin (HbA(1c))

Randomised vs glimepiride 8 mg

Probably lowered long-term blood sugar

−0.62−0.83 to −0.42

liraglutide 1.8 mg vs glimepiride 8 mg

As reported

difference −0.62, 95% CI −0.83 to −0.42 · the paper's word: change in proportion of glycosylated haemoglobin (HbA(1c))

Who was studied, and how

746people with hypertension, in this paper

The trial randomly assignedassigned by chance

liraglutide 1.2 mg
glimepiride 8 mg

Probably lowered long-term blood sugar−0.33

randomised

The trial randomly assignedassigned by chance

liraglutide 1.8 mg
glimepiride 8 mg

Probably lowered long-term blood sugar−0.62

randomised

the abstract, start to end

with liraglutide 1.2 mg (difference -0.33%; 95% CI -0.53 to -0.13, p=0.0014) and 1.14% (1.24%) with liraglutide 1.8 mg (-0.62; -0.83 to -0.42, p<0.0001).

← favours treatmentfavours comparator →
could be chance
Change in proportion of glycosylated haemoglobin (HbA(1c))liraglutide 1.2 mg vs glimepiride 8 mg
−0.33−0.53 to −0.13
Change in proportion of glycosylated haemoglobin (HbA(1c))liraglutide 1.8 mg vs glimepiride 8 mg
−0.62−0.83 to −0.42
GLP-1 receptor agonistsGlycemic control
1 / 4

376 papers cite itlatest 60 shown

2009
2014
2015
2016
2017
2018
2019
2020
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

5 trials

Full record →Abstract, authors, funding and every citing paper · PMID 18819705